Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

Amgen today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023.

Selecta Biosciences is narrowing its focus

Selecta Biosciences announced Thursday that it will stop investment in most of its pipeline assets except for a treatment for chronic refractory gout licensed to

August 18, 2023

New DELIVER guidelines aim to accelerate nanomedicine development

They’re tiny drug-delivery systems 1000 times smaller than a human hair, but while nanomedicines have long been hailed as the future for treating debilitating and

September 6, 2024

Study finds marriage linked to optimal aging in men

A new study that followed over 7,000 Canadians, middle-aged and older, for approximately three years found that married men or men who became married during

August 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.